. . "1"^^ . . "Kizek, Ren\u00E9" . "Stiborov\u00E1, Marie" . "Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice." . "Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances" . "induced cardiomyopathy; doxorubicin interactions; electrochemical biosensor; in-vivo; cytochromes P450; phase-II; peroxidase-mediated oxidation; cell-cycle arrest; metastatic breast-cancer; nanocarriers; adduct formation; ellipticine; anthracyclines"@en . . . "Pharmacology and Therapeutics" . . "Burda, Jaroslav" . . . . "http://dx.doi.org/10.1016/j.pharmthera.2011.07.006" . "8"^^ . "Over the past forty years, anthracyclines and ellipticines have attracted attention as promising cytostatics. In this review, we focus on their mechanisms of cytoxicity, DNA-damaging effects and adverse side-effects. We also summarize ways to enhance the therapeutic effects of these drugs together with a decrease in their adverse effects. Current drug design strategies are focused on drug bioavailability and their tissue targeting, whereas drug delivery to specific intracellular compartments is rarely addressed. Therefore, therapies utilizing the antineoplastic activities of anthracyclines and ellipticines combined with novel strategies such as nanotechnologies for safer drug delivery, as well as strategies based on gene therapy, could significantly contribute to medical practice."@en . . . . "133" . "Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances"@en . . "Hrab\u011Bta, Jan" . "Frei, Eva" . . . "Adam, Vojt\u011Bch" . . "RIV/00216208:11310/12:10126251" . "[A68F24C2EDAC]" . . "14"^^ . . . "I, P(GAP205/10/0228), P(GAP301/10/0356), P(IAA401990701)" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "RIV/00216208:11310/12:10126251!RIV13-GA0-11310___" . "Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances" . "Eckschlager, Tom\u00E1\u0161" . . "122869" . . "0163-7258" . . . . "000299979600003" . "Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances"@en . "1" . . . "10.1016/j.pharmthera.2011.07.006" . . . . "Smutn\u00FD, Svatopluk" . "11310" .